Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 31Esophageal Squamous Cell Carcinoma 17Carcinoma, Squamous Cell 5Adenocarcinoma 3Neoplasms 2Postoperative Complications 1Pathologic Complete Response 1Pain, Postoperative 1Lymphatic Metastasis 1Loco-regional Esophageal Cancer 1Deglutition Disorders 1Clinical Stage I Esophageal Adenocarcinoma AJCC v8 1Anastomotic Leak 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Epirubicin 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Observation 2Monatide (IMS 3015) 2Metformin 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × Esophagectomy × Clear all
NCT04006041 2019-12-26

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Sun Yat-sen University

Phase 2 Unknown
44 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon âš¡